Redwood Pharma

Mindre end 1K følgere

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse28.7.2024, 12.30

Redwood Pharma files for bankruptcy

Selskabsmeddelelse26.6.2024, 09.00

Redwood Pharma provides a new update regarding divestment of company assets

Pressemeddelelse12.6.2024, 10.00

Redwood Pharma provides an update on the process for divesting the company's assets

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse23.5.2024, 11.00

Redwood Pharma provides an update on the company's future

Pressemeddelelse8.5.2024, 06.30

Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle

Pressemeddelelse7.5.2024, 06.30

Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements

Pressemeddelelse6.5.2024, 13.00

Redwood Pharma's board subscribes to units in the ongoing new issue

Pressemeddelelse28.2.2024, 07.30

Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle

Pressemeddelelse20.12.2023, 08.10

Redwood Pharma's CEO Martin Vidaeus in year-end interview

Pressemeddelelse19.12.2023, 07.00

Redwood Pharma to participate in the JP Morgan Healthcare Conference

Selskabsmeddelelse30.11.2023, 07.30

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Pressemeddelelse22.11.2023, 07.30

Redwood Pharma to participate in the NLS Days partner conference in Copenhagen

Pressemeddelelse19.10.2023, 09.15

Redwood Pharma to participate in the BIO-Europe partnering conference in Munich

Selskabsmeddelelse31.5.2023, 21.10

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

Pressemeddelelse17.3.2023, 12.00

Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye

Pressemeddelelse24.1.2023, 07.30

Redwood Pharma takes important steps towards the commercial production of its dry eye product

Selskabsmeddelelse15.12.2022, 16.00

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

Pressemeddelelse19.10.2022, 13.18

Interview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm

Pressemeddelelse14.10.2022, 06.30

Redwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022

Pressemeddelelse3.10.2022, 13.42

Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.